OncoMatch/Clinical Trials/NCT06510660

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

Is NCT06510660 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies adebrelimab for esophageal squamous cell carcinoma.

Phase 2RecruitingFujian Medical University Union HospitalNCT06510660Data as of May 2026

Treatment: adebrelimab — To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Disease stage

Required: Stage II, III, IVA, IVB

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: immunotherapy

Prior treatment with immunotherapy

Lab requirements

Blood counts

Kidney function

Liver function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify